Modular Manufacturing

Modular Facilities in Pharmaceutical and Biotechnology Market (2nd Edition) by Type of Modular Construct, Type of Construction Component, Purpose of Facility, Facility Area, Scale of Operation, Type of Industry, Type of Product (Biosimilars, Cell and Gene Therapies, Monoclonal Antibodies, Vaccines and Other Products), and by Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,899

  • Published
    April 2021

  • Pages
    302

  • View Count
    26316

  • Buy Now

Example Insights

Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Context Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Facility-Providers Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Type-of-Industry-Serve Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Location-and-Type
Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Type-of-Partnership Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Cleanroom-Providers Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Conventional-Facilities Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Future-Growth-Opportunities
Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Likely-Growth-Scenarios Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Type-of-Product Modular-Facilities-in-Pharmaceutical-and-Biotechnology-Market-Purpose-of-Facility  

 

Overview

Industry stakeholders are regularly in pursuit of building strategic advantage(s) associated with product development and production processes; one of the ways to drive this is to establish flexible manufacturing capacity and deploy the associated infrastructure / facilities swiftly. Over the past few years, a large number of factors have converged to transform the facility construction paradigm within the pharmaceutical and biotechnology industries. The aforementioned factors include optimization of capital expenditure, reduction of construction timelines, integration of single-use technologies (e.g. single-use bioreactors), and the necessity to develop capabilities to support personalized medicine (driven by the need to address therapeutic requirements for rare / orphan clinical conditions). Pre-engineered, modular facilities have emerged as a versatile solution to the abovementioned problem statement. In fact, this approach has been demonstrated to be capable of addressing several challenges, such as weather-related concerns, shortage of skilled labor, labor contract constraints and delays in supply of raw materials. Furthermore, traditional production platforms require extensive investments, in terms of both capital and time. Such facilities also consist of built-in operating equipment attached to the facility substructure, necessitating extensive renovations for equipment upgrade and reconfiguration. On the other hand, in a modular approach, individual units of a facility and the required equipment (which is integrated into the facility design) are fabricated in factories away from the actual location of the facility. Moreover, the aforementioned facility templates are built to be flexible, with provisions for future expansion of area and capacity. This has been shown to significantly improve infrastructure development and installation time. For instance, in 2018, Janssen Pharmaceuticals, in collaboration with Legend Biotech, built a modular, commercial-scale facility, using a hybrid construction approach (which involved a combination of off-site and on-site construction); the edifice spanned 38,000 sq ft and was completed within a record time of nine months. It is also worth highlighting that the recent surge in demand for biopharmaceuticals due to COVID-19 pandemic has fueled the need for strategic changes in bioprocessing. In June 2020, Sanofi invested USD 554 million in the construction of a state-of-the-art modular vaccine production facility, in Neuville sur Saône, France, with the capacity to produce three to four vaccines simultaneously. 

Productivity in the conventional construction has been shown to never exceed 80%; this is usually attributed to logistical delays (transport of building material to the construction site) and inconsistent availability of manpower. On the other hand, in the modular construction approach, productivities of over 100% (up to 140%) have been reported. This can primarily be attributed to the fact that the latter method is executed in a controlled, fabrication shop environment and much of the fabrication process is automated (which eliminates the excessive reliance on manual labor), thereby, alleviating external risks and minimizing schedule overruns. Next generation construction methods are projected to evolve under the effect of current market dynamics. Several important developments in the pharmaceutical industry are influencing the design and construction of manufacturing facilities. Therefore, companies must retain the flexibility offered by contract manufacturers when they carry insourced projects in-house. Further, the advent of new modalities and next-generation drugs, such as cell and gene therapies and highly potent small molecule active pharmaceutical ingredients, which require specialized manufacturing facilities and equipment while avoiding cross-contamination and ensuring operator safety and protection, adds to need of platforms that are adaptable. Such trends, coupled to the increased pressure to improve efficiency, lower operating costs and acceleration of the drug development process, are considered to be the key drivers of the adoption of modular solutions. Moreover, biopharma industry continues to seek innovative ways of optimizing drug development costs and timelines. Off-site design and modularization demonstrate great potential to provide the industry with the agility to reduce the overall time to market for a particular product.

Scope of the Report

The “Modular Facilities in Pharmaceutical and Biotechnology Market by Type of Modular Construct (Hybrid Skid, Plug-and-Play, Skid-Mounted, Truckable and Others), Type of Construction Component (Base Building, Electrical System, Mechanical System, Process Equipment, Process Piping, Process Utilities and Other Components), Purpose of Facility (Aseptic Filling, Manufacturing, Research and Development and Others), Facility Area (Very Small, Small, Mid-Sized, Large and Very Large), Scale of Operation (Clinical and Commercial), Type of Industry (Pharmaceutical and Biotechnology), Type of Product (Biosimilars, Cell and Gene Therapies, Monoclonal Antibodies, Vaccines and Other Products), and by Key Geographical Regions (North America, Europe, Asia, Middle East and North Africa, Latin America and Rest of the World): Industry Trends and Global Forecasts, 2021-2030” report features an extensive study of the current market landscape and future potential of the players engaged in offering services for modular facility construction for biotechnology and pharmaceutical industries. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report features:

  • A review of the market landscape of modular facilities along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), geographical coverage, GMP compliance construction and type of industry served (pharmaceutical, biotechnology or others). It also includes details related to certifications obtained and COVID-19 related initiatives undertaken by modular service providers.
  • A review of the market landscape of modular cleanrooms along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world), type of industry served (pharmaceutical, biotechnology or others), type of modular cleanrooms (softwall and hardwall), type of modular cleanroom components (air handling units / HVAC system, fan filter units, laminar flow units, air showers, pass throughs, cleanroom furniture / furnishings, plumbing / piping, lighting / electricals). It also includes details related to regulatory approvals and certifications.
  • An analysis of the partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021 (till January), covering facility construction agreements, cleanroom construction agreements, service alliances, service agreements and other relevant types of deals.
  • An analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. We have provided a case study on JHL Biotech's KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China. It also includes information on modular projects received by key pharma / biotech players based on location, type and area of facility.
  • An insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players, along with information on their number of facilities, type of facility, purpose, investments made in modular projects, area of facility and location of headquarters.
  • Elaborate profiles of key players that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to modular facility- focused services, modular projects, recent developments and an informed future outlook.
  • A review of emerging trends, including the combination of single-use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.
  • A detailed discussion on the various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs and the anticipated increase in the adoption of modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs. It also highlights trends, such as expansion of existing facilities and adoption of modular facilities by emerging start-ups and small companies.

One of the key objectives of this report was to estimate the existing market size and the future growth potential within the pharmaceutical / biotechnology modular manufacturing market. We have developed informed estimates on the financial evolution of the market, over the period 2021-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of modular construct (hybrid skid, plug-and-Play, skid-mounted, truckable and others), [B] type of construction component (base building, electrical system, mechanical system, process equipment, process piping, process utilities, and other components), [C] purpose of facility (aseptic filling, manufacturing, research and development, and others), [D] facility area (very small, small, mid-sized, large and very large plants), [E] scale of operation (clinical and commercial), [F] type of industry (pharmaceutical and biotechnology), [G] type of product (biosimilars, cell and gene therapies, monoclonal antibodies, vaccines, and other products) and [H] key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and rest of the world). In order to account for future uncertainties and to add robustness to our forecast model, we have provided three scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth. 

The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals (in alphabetical order):

  • Alan de Zayas (Modular Building Manufacturing and Construction Team, Avon Modular Construction)
  • François Abiven (Executive Vice-President Global Business Unit BLS and Luca Mussati Vice President, Pharma and Biotech Life Sciences, Exyte)
  • Maik Jornitz (President and Chief Executive Officer, G-CON Manufacturing)
  • Pär Almhem (President, Modwave)
  • Sulogna Roy (Ex Sales Manager, Zeton)
  • Vernon Solomon (Specialist in Modular Design for Cleanrooms and Close Tolerance Temperature and Humidity Control, Environmental Systems Corporation)

All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the key service providers engaged in domain of modular construction? What are the current trends fueling the adoption of modular construction solutions in the pharma / biotech industries?
  • Which key regions are targeted by pharma / biotech companies for expanding their existing facilities and capabilities?
  • What type of product lines are actively supported by integrated modular solutions in facility design and construction?
  • What are the recent initiatives undertaken by modular manufacturers in order to overcome the challenges related to the COVID-19 pandemic? 
  • Which regions are the current hubs for modular construction service providers?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • How is the current and future opportunity likely to be distributed across key market segments?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the insights captured in our research. It offers a high-level view on the current state of modular facilities in pharmaceutical and biotechnology market and its likely evolution in the short-mid and long term.

Chapter 3 is an introductory chapter that highlights important concepts related to modular facilities, including a discussion on the historical background of modular construction, the concept of modularization, type of modular constructs available in the market. The chapter also features information on modular construction process, modular construction in pharmaceutical industry, advantages of modular construction, overview of modular pharmaceutical cleanrooms, cleanroom classifications and standards. Further, it highlights information on regulations and standards concerning modular cleanroom construction.

Chapter 4 includes information on close to 35 modular facility providers. It features a detailed analysis on modular facilities along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world) and geographical coverage. The chapter also features GMP compliance construction and type of industry served (pharmaceutical, biotechnology or others). Further, the chapter provides information on quality certifications obtained and COVID-19 related initiatives undertaken by modular service providers.

Chapter 5 includes information on more than 170 modular cleanroom providers. It features a detailed analysis on modular cleanrooms along with information on their year of establishment, company size (small, mid-sized or large), location of headquarters (North America, Europe, Asia and rest of the world). The chapter also features analysis on type of industry served (pharmaceutical, biotechnology or others), type of modular cleanrooms (softwall and hardwall), type of modular cleanroom components (air handling units / HVAC system, fan filter units, laminar flow units, air showers, pass throughs, cleanroom furniture / furnishings, plumbing / piping, lighting / electricals). Further, the chapter provides information on details related to regulatory approvals and certifications.

Chapter 6 features tabulated profiles of key that provide a wide range of modular manufacturing solutions to pharmaceutical and biotechnology industries. Each profile features a brief overview of the company (including information on year of establishment, number of employees, location of headquarters and key members of the executive team), details related to modular facility- focused services, modular projects, recent developments and an informed future outlook.

Chapter 7 presents in-depth analysis on partnerships that have been inked by stakeholders in this domain, during the period between 2012 and 2021 (till January), covering facility construction agreements, cleanroom construction agreements, service alliances, service agreements and other relevant types of deals.

Chapter 8 presents an insightful analysis of modular projects undertaken across key geographical regions, featuring information on type of facility, facility area, most active manufacturers, most active clients, location of facility. The chapter also features It also features a a case study on JHL Biotech's KUBio biomanufacturing facility, which was constructed by GE Healthcare Life Sciences in China. Further, the chapter provides information on modular projects received by key pharma / biotech players based on location, type and area of facility.

Chapter 9 present an insightful analysis on facility construction trends in the pharmaceutical industry for the last five years, highlighting facility construction projects established by top 20 pharma / biotech players, along with information on their number of facilities, type of facility, purpose, investments made in modular projects, area of facility and location of headquarters.

Chapter 10 presents a comprehensive market forecast analysis, the existing market size and the future growth potential within the pharmaceutical / biotechnology modular manufacturing market, 2021 - 2030. The chapter provides likely distribution of current and forecasted opportunity based on type of modular construct (hybrid skid, plug-and-Play, skid-mounted, truckable and others), type of construction component (base building, electrical system, mechanical system, process equipment, process piping, process utilities, and other components), purpose of facility (aseptic filling, manufacturing, research and development, and others),  facility area (very small, small, mid-sized, large and very large plants), scale of operation (clinical and commercial), type of industry (pharmaceutical and biotechnology), type of product (biosimilars, cell and gene therapies, monoclonal antibodies, vaccines, and other products) and key geographical regions (North America, Europe, Asia, Middle East and North Africa, Latin America and rest of the world).

Chapter 11 presents information on emerging trends, including the combination of single-use technologies / continuous processing technologies with modular facilities, the shift to using smaller, multi-purpose modular facilities, and technological advancements in modular construction processes.

Chapter 12 provides information on various growth drivers, such as the development of personalized medicines, biosimilars, orphan drugs and the anticipated increase in the adoption of modular solutions in emerging markets by pharmaceutical / biopharmaceutical CMOs. Further, the chapter also highlights current trends, such as expansion of existing facilities and adoption of modular facilities by emerging start-ups and small companies.

Chapter 13 summarizes the entire report. It presents a list of key takeaways and offers an independent opinion on the current market scenario. Further, it summarizes the various evolutionary trends that are likely to influence the future of this market.

Chapter 14 is a collection of executive insights of the discussion that were held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interview held with Maik Jornitz (Chief Executive Officer, G-CON Manufacturing), Pär Almhem (President, Modwave), Vernon Solomon (President, Environmental Systems Corporation), François Abiven (Executive Vice President, Exyte) and Luca Mussati (Vice President Technology and Innovation, Exyte), Alan de Zayas (Modular Building Manufacturing and Construction Team,  Avon Modular Construction, Sulogna Roy (Ex Sales Manager, Zeton)

Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 16 is an appendix, which consists the list of companies and organizations mentioned in the report.

Table Of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1. Chapter Overview
3.2. Historical Background
3.3. The Concept of Modularization
3.3.1. Types of Modular Constructs
3.3.2. Modular Construction Process

3.4. Modular Construction in the Pharmaceutical Industry
3.4.1. Advantages of Modular Construction in the Pharmaceutical Industry
3.4.2. Modular Pharmaceutical Cleanrooms
3.4.2.1. Cleanroom Classifications and Current Standards
3.4.2.2. Regulations and Standards Concerning Modular Cleanroom Construction

3.5. Advantages of Modular Cleanrooms
3.6. Challenges and Future Prospects

4. MARKET LANDSCAPE: MODULAR FACILITY MANUFACTURERS
4.1. Chapter Overview
4.2. Modular Facility Manufacturers: Overall Market Landscape
4.2.1 Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Geographical Coverage
4.2.5. Analysis by Geographical Coverage and GMP Compliance
4.2.6. Analysis by Type of Industry Served
4.2.7. Analysis by Geographical Coverage and Type of Industry Served
4.2.8. Historical and Current Market Landscape Trend Analysis
4.2.8.1 Analysis by Company Size, Geographical Coverage and Type of Industry Served
4.2.9. Quality Certifications
4.3. Modular Facility Manufacturers: COVID-19-related Initiatives

5. MARKET LANDSCAPE: MODULAR CLEANROOM PROVIDERS
5.1. Chapter Overview
5.2. Modular Cleanroom Providers: Overall Market Landscape
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Industry Served
5.2.5. Analysis by Type of Modular Cleanroom Offered
5.2.6. Analysis by Type of Industry Served and Type of Modular Cleanrooms
5.2.7. Analysis by Type of Cleanroom Component Offered
5.2.8. Analysis by Type of Modular Cleanroom and Cleanroom Component Offered
5.2.9. Analysis by Type of Industry Served and Type of Cleanroom Component Offered
5.2.10. Analysis by Location of Headquarters and Type of Industry Served
5.2.11. Analysis by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom
5.2.12. Regulatory Approvals and Certifications

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Cytiva
6.2.1. Company Overview
6.2.2. Modular Facility-related Services
6.2.3. Modular Projects
6.2.4. Recent Developments and Future Outlook

6.3. G-CON Manufacturing
6.3.1. Company Overview
6.3.2. Modular Facility-related Services
6.3.3. Modular Projects 
6.3.4. Recent Developments and Future Outlook

6.4. Pharmadule Morimatsu
6.4.1. Company Overview
6.4.2. Modular Facility-related Services
6.3.3. Modular Projects 
6.3.4. Recent Developments and Future Outlook

6.5. NNE
6.5.1. Company Overview
6.5.2. Modular Facility-related Services
6.5.3. Modular Projects
6.5.4. Recent Developments and Future Outlook

6.6. IPM Technologies
6.6.1. Company Overview
6.6.2. Modular Facility-related Services
6.6.3. Modular Projects
6.6.4. Recent Developments and Future Outlook

6.7. KeyPlants
6.7.1. Company Overview
6.7.2. Modular Facility-related Services
6.7.3. Modular Projects
6.7.4. Recent Developments and Future Outlook 

6.8. Germfree Laboratories
6.8.1. Company Overview
6.8.2. Modular Facility-related Services
6.8.3. Modular Projects
6.8.4. Recent Developments and Future Outlook

6.9. ModuleCO Pharma
6.9.1. Company Overview
6.9.2. Modular Facility-related Services
6.9.3. Modular Projects
6.9.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Types of Partnership Models

7.3. Modular Facility Providers: Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.2.1. Analysis by Year and Type of Partnership
7.3.3. Analysis by Type of Product
7.3.3.1. Analysis by Type of Partnership and Type of Product
7.3.4. Analysis by Type of Modular Facility
7.3.4.1. Analysis by Type of Product and Type of Modular Facility
7.3.5. Most Active Players: Analysis by Number of Partnerships

7.3.6. Regional Analysis
7.3.6.1. Analysis by Location of Headquarters of Partner
7.3.6.2. Analysis by Location of Facility
7.3.6.3. Analysis by Type of Partnership and Location of Facility
7.3.6.4. Analysis by Type of Product and Location of Facility
7.3.7. Intercontinental and Intracontinental Partnerships
7.3.7.1. Country-wise Distribution
7.3.7.2. Regional Distribution
7.3.7.3 Analysis by Type of Partnership, Type of Product, Location of Facility and Type of Agreement

8. FEASIBILITY STUDY
8.1. Chapter Overview
8.2. Modular Facility Projects Undertaken in the Pharmaceutical / Biotechnology Industry
8.3. Analysis by Type of Facility
8.4. Analysis by  Facility Area
8.5. Analysis by Type of Facility and Facility Area
8.6. Most Active Manufacturers: Analysis by Number of Projects Delivered
8.7. Most Active Clients: Analysis by Number of Projects Received
8.8. Analysis by Location of Facility
8.9. Analysis by Client and Location of Facility
8.10. Modular versusConventional Construction Methods
8.11. Return on Investment
8.12. Case Study: Facility Based on KUBio Platform
8.12.1. GE Healthcare’s KUBio Platform: Overview
8.12.2. JHL Biotech’s KUBio Modular Project in China: Overview and Construction Details

9. FACILITY CONSTRUCTION TRENDS IN THE PHARMACEUTICAL INDUSTRY
9.1. Chapter Overview
9.2. Facility Construction Projects Undertaken in the Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2016-2020 (Till December)
9.2.1. Analysis by Number of Facilities
9.2.2. Analysis by Type of Facility
9.2.3. Analysis by Purpose of Facility
9.2.4. Analysis by Investment
9.2.5. Analysis by Facility Area
9.2.6. Analysis by Location of Headquarters

10. MARKET FORECAST
10.1. Chapter Overview
10.2. Forecast Methodology and Key Assumptions
10.3. Modular Facilities Market, 2021-2030
10.4. Modular Facilities Market: Distribution by Type of Modular Construct
10.4.1. Modular Facilities Market for Hybrid Skid Modular Construct, 2021-2030
10.4.2. Modular Facilities Market for Plug-and-Play Modular Construct, 2021-2030
10.4.3. Modular Facilities Market for Skid-Mounted Modular Construct, 2021-2030
10.4.4. Modular Facilities Market for Truckable Modular Construct, 2021-2030
10.4.5. Modular Facilities Market for Others, 2021-2030

10.5. Modular Facilities Market: Distribution by Type of Construction Component
10.5.1. Modular Facilities Market for Base Building, 2021-2030
10.5.2. Modular Facilities Market for Electrical System, 2021-2030
10.5.3. Modular Facilities Market for Mechanical System, 2021-2030
10.5.4. Modular Facilities Market for Process Equipment, 2021-2030
10.5.5. Modular Facilities Market for Process Piping, 2021-2030
10.5.6. Modular Facilities Market for Process Utilities, 2021-2030
10.5.7. Modular Facilities Market for Other Components, 2021-2030

10.6 Modular Facilities Market: Distribution by Purpose of Facility
10.6.1. Modular Facilities Market for Aseptic Filling, 2021-2030
10.6.2. Modular Facilities Market for Manufacturing, 2021-2030
10.6.3. Modular Facilities Market for Research and Development, 2021-2030
10.6.4. Modular Facilities Market for Others, 2021-2030

10.7. Modular Facilities Market: Distribution by Facility Area
10.7.1. Modular Facilities Market for Very Small Plants, 2021-2030
10.7.2. Modular Facilities Market for Small Plants, 2021-2030
10.7.3. Modular Facilities Market for Mid-Sized Plants, 2021-2030
10.7.4. Modular Facilities Market for Large Plants, 2021-2030
10.7.5. Modular Facilities Market for Very Large Plants, 2021-2030

10.8. Modular Facilities Market: Distribution by Scale of Operation
10.8.1. Modular Facilities Market for Clinical Operations, 2021-2030
10.8.2. Modular Facilities Market for Commercial Operations, 2021-2030

10.9. Modular Facilities Market: Distribution by Type of Industry
10.9.1. Modular Facilities Market for Pharmaceutical, 2021-2030
10.9.2. Modular Facilities Market for Biotechnology, 2021-2030

10.10. Modular Facilities Market: Distribution by Type of Product
10.10.1. Modular Facilities Market for Biosimilars, 2021-2030
10.10.2. Modular Facilities Market for Cell and Gene Therapies, 2021-2030
10.10.3. Modular Facilities Market for Monoclonal Antibodies, 2021-2030
10.10.4. Modular Facilities Market for Vaccines, 2021-2030
10.10.5. Modular Facilities Market for Other Products, 2021-2030

10.11. Modular Facilities Market: Distribution by Key Geographical Regions
10.11.1. Modular Facilities Market for North America, 2021-2030
10.11.2. Modular Facilities Market for Europe, 2021-2030
10.11.3. Modular Facilities Market for Asia, 2021-2030
10.11.4. Modular Facilities Market for Middle East and North Africa, 2021-2030
10.11.5. Modular Facilities Market for Latin America, 2021-2030
10.11.6. Modular Facilities Market for Rest of the World, 2021-2030

10.12. Concluding Remarks

11. PREVELANT AND EMERGING INDUSTRY TRENDS
11.1. Chapter Overview
11.2. The Pharmaceutical Industry is Rapidly Adopting Smaller Modular Facilities
11.3. Integration of Single Use Technologies with Modular Facilities Offers Flexibility and Economic Benefits
11.4. Continuous Processing Technologies Offer Added Advantages to the Modular Approach
11.5. Modular Facilities are Integrated with Advanced Technology Emphasizing Improved Productivity
11.6. The Market is Abuzz with Partnership Activity as Service Providers Form Strategic Alliances to Expand their Portfolios

12. FUTURE GROWTH OPPORTUNITIES
12.1. Chapter Overview
12.2. The Modular Approach is Popular Amongst Start-Ups and Small Companies
12.3. In Order to Accelerate Time to Market and Stay Competitive, Several Biosimilar Manufacturers are Expected to Install Modular Facilities
12.4. Addressing the Niche Requirements, Orphan Indications Offer Additional Opportunities for Modular Facility Manufacturers
12.5. Emerging Regions are Likely to be Attractive Markets for Stakeholders in the Long Term
12.6. Expansions of Existing Facilities Using Modular Solutions are Projected to Increase Significantly
12.7. Several Contract Manufacturing Organizations have Adopted Modular Solutions

13. CONCLUSION
13.1. Chapter Overview
12.2. Key Takeaways

14. EXECUTIVE INSIGHTS
14.1. Chapter Overview
14.2. G-CON Manufacturing
14.2.1. Company Snapshot
14.2.2. Interview Transcript: Maik Jornitz, Chief Executive Officer

14.3. Modwave
14.3.1. Company Snapshot
14.3.2. Interview Transcript: Pär Almhem, President

14.4. Environmental Systems Corporation
14.4.1. Company Snapshot
14.4.2. Interview Transcript: Vernon Solomon, President

14.5. Exyte
14.5.1. Company Snapshot
14.5.2. Interview Transcript: François Abiven, Executive Vice President, Luca Mussati, Vice President, Technology and Innovation

14.6. Avon Modular Construction
14.6.1. Company Snapshot
14.6.2. Interview Transcript: Alan de Zayas, Modular Building Manufacturing and Construction Team

14.7. Zeton
14.7.1. Company Snapshot
14.7.2. Interview Transcript: Sulogna Roy, Sales Manager / Project Manager

14. APPENDIX 1:  TABULATED DATA

15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Applications of Modular Constructs
Figure 3.2 Steps Involved in the Modular Construction Approach
Figure 3.3 Comparison of Construction Timelines of Modular and Conventional Buildings
Figure 3.4 Advantages Offered by the Modular Construction Approach
Figure 4.1 Modular Facility Manufacturers: Distribution by Year of Establishment
Figure 4.2 Modular Facility Manufacturers: Distribution by Company Size
Figure 4.3 Modular Facility Manufacturers: Continent-wise Distribution
Figure 4.4 Modular Facility Manufacturers: Country-wise Distribution
Figure 4.5 Modular Facility Manufacturers: Distribution by Geographical Coverage
Figure 4.6 Modular Facility Manufacturers: Distribution by Geographical Coverage and GMP Compliance
Figure 4.7 Modular Facility Manufacturers: Distribution by Type of Industry Served
Figure 4.8 Modular Facility Manufacturers: Distribution by Geographical Coverage and Type of Industry Served
Figure 4.9 Modular Facility Manufacturers: Distribution by Company Size, Geographical Coverage and Type of Industry Served
Figure 5.1 Modular Cleanroom Providers: Distribution by Year of Establishment
Figure 5.2 Modular Cleanroom Providers: Distribution by Company Size
Figure 5.3 Modular Cleanroom Providers: Distribution by Location of Headquarters
Figure 5.4 Modular Cleanroom Providers: Distribution by Type of Industry Served
Figure 5.5 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Figure 5.6 Modular Cleanroom Providers: Distribution by Type of Industry Served and Type of Modular Cleanroom Offered
Figure 5.7 Modular Cleanroom Providers: Distribution by Type of Cleanroom Component Offered
Figure 5.8 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered and Type of Cleanroom Component Offered
Figure 5.9 Modular Cleanroom Providers: Distribution by Type of Industry Served and Type of Modular Cleanroom Component Offered
Figure 5.10 Modular Cleanroom Providers: Distribution by Location of Headquarters and Type of Industry Served
Figure 5.11 Modular Cleanroom Providers: Distribution by Location of Headquarters, Type of Industry Served and Modular Cleanroom
Figure 6.1 Cytiva: Modular Facility-related Services
Figure 6.2 Cytiva: Stages of KUBio Facility Project
Figure 6.3 Cytiva: Single-use Technology Portfolio
Figure 6.4 G-CON Manufacturing: Modular Facility-related Services
Figure 6.5 Pharmadule Morimatsu: Modular Facility-related Services
Figure 6.6 Pharmadule Morimatsu: Process of Modular Facility Construction
Figure 6.7 NNE: Modular Facility-related Services
Figure 6.8 NNE: Benefits of Bio on Demand Facility
Figure 6.9 IPM Technologies: Types of Modular Production Units
Figure 6.10 IPM Technologies: Features of ISOdule Units
Figure 6.11 IPM Technologies: Applications of Modular Facilities
Figure 6.12 KeyPlants: Modular Facility-related Services
Figure 6.13 Germfree Laboratories: Modular Facility-related Services
Figure 6.14 Germfree Laboratories: Types of Lab Modules
Figure 6.15 ModuleCo Pharma: Key Features of Modular Facilities
Figure 7.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2021 (Till January)
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 7.4 Partnerships and Collaborations: Distribution by Type of Product
Figure 7.5 Partnerships and Collaborations: Distribution by Type of Product and Type of Partnership
Figure 7.6 Partnerships and Collaborations: Distribution by Type of Modular Facility
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Product and Type of Modular Facility
Figure 7.8 Partnerships and Collaborations: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Figure 7.10 Partnerships and Collaborations: Distribution by Location of Facility
Figure 7.11 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Facility
Figure 7.12 Partnerships and Collaborations: Distribution by Type of Product and Location of Facility
Figure 7.13 Partnerships and Collaborations: Country-wise Distribution
Figure 7.14 Partnerships and Collaborations: Continent-wise Distribution
Figure 7.15 Partnerships and Collaborations: Distribution by Type of Partnership, Type of Product, Location of Facility and Type of Agreement
Figure 8.1 Feasibility Study: Key Players and their Clients
Figure 8.2 Feasibility Study: Distribution by Type of Facility
Figure 8.3 Feasibility Study: Distribution by Facility Area
Figure 8.4 Feasibility Study: Distribution by Type of Facility and Facility Area
Figure 8.5 Feasibility Study: Distribution by Modular Facility Providers
Figure 8.6 Feasibility Study: Distribution by Geography
Figure 8.7 Feasibility Study: Modular versus Conventional Construction Approaches
Figure 8.8 Feasibility Study: Cost Saving Potential
Figure 8.9 Feasibility Study: KUBio Facility Construction Process
Figure 8.10 Feasibility Study: KUBio Facility Construction Timeline
Figure 9.1 Facility Construction Trends in Pharmaceutical Industry: Distribution by Number of Facilities
Figure 9.2 Facility Construction Trends in Pharmaceutical Industry: Distribution by Type of Facility
Figure 9.3 Facility Construction Trends in Pharmaceutical Industry: Distribution by Purpose of Facility
Figure 9.4 Facility Construction Trends in Pharmaceutical Industry: Distribution by Investment
Figure 9.5 Facility Construction Trends in Pharmaceutical Industry: Distribution by Facility Area
Figure 9.6 Facility Construction Trends in Pharmaceutical Industry: Distribution by Location of Headquarters
Figure 10.1 Modular Facilities in Pharmaceutical and Biotechnology Market, 2021 and 2030 (USD Million)
Figure 10.2 Modular Facilities Market: Distribution by Type of Modular Construct, 2021-2030
Figure 10.3. Modular Facilities Market for Hybrid Skid Modular Construct, 2021-2030 (USD Million)
Figure 10.4 Modular Facilities Market for Plug-and-Play Modular Construct, 2021-2030 (USD Million)
Figure 10.5 Modular Facilities Market for Skid-Mounted Modular Construct, 2021-2030 (USD Million)
Figure 10.6 Modular Facilities Market for Truckable Modular Construct, 2021-2030 (USD Million)
Figure 10.7 Modular Facilities Market for Others, 2021-2030 (USD Million)
Figure 10.8 Modular Facilities Market: Distribution by Type of Construction Component, 2021 and 2030
Figure 10.9 Modular Facilities Market for Base Building, 2021-2030 (USD Million)
Figure 10.10 Modular Facilities Market for Electrical System, 2021-2030 (USD Million)
Figure 10.11 Modular Facilities Market for Mechanical System, 2021-2030 (USD Million)
Figure 10.12 Modular Facilities Market for Process Equipment, 2021-2030 (USD Million)
Figure 10.13 Modular Facilities Market for Process Piping, 2021-2030 (USD Million)
Figure 10.14 Modular Facilities Market for Process Utilities, 2021-2030 (USD Million)
Figure 10.15 Modular Facilities Market for Other Components, 2021-2030 (USD Million)
Figure 10.16 Modular Facilities Market: Distribution by Purpose of Facility, 2021 and 2030
Figure 10.17 Modular Facilities Market for Aseptic Filling, 2021-2030 (USD Million)
Figure 10.18 Modular Facilities Market for Manufacturing, 2021-2030 (USD Million)
Figure 10.19 Modular Facilities Market for Research and Development, 2021-2030 (USD Million)
Figure 10.20 Modular Facilities Market for Others, 2021-2030 (USD Million)
Figure 10.21 Modular Facilities Market: Distribution by Facility Area, 2021 and 2030
Figure 10.22 Modular Facilities Market for Very Small Plants, 2021-2030 (USD Million)
Figure 10.23 Modular Facilities Market for Small Plants, 2021-2030 (USD Million)
Figure 10.24 Modular Facilities Market for Mid-Sized Plants, 2021-2030 (USD Million)
Figure 10.25 Modular Facilities Market for Large Plants, 2021-2030 (USD Million)
Figure 10.26. Modular Facilities Market for Very Large Plants, 2021-2030 (USD Million)
Figure 10.27 Modular Facilities Market: Distribution by Scale of Operation, 2021 and 2030
Figure 10.28 Modular Facilities Market for Clinical Operations, 2021-2030 (USD Million)
Figure 10.29 Modular Facilities Market for Commercial Operations, 2021-2030 (USD Million)
Figure 10.30 Modular Facilities Market: Distribution by Type of Industry, 2021-2030
Figure 10.31 Modular Facilities Market for Pharmaceutical, 2021-2030 (USD Million)
Figure 10.32 Modular Facilities Market for Biotechnology, 2021-2030 (USD Million)
Figure 10.33 Modular Facilities Market: Distribution by Type of Product, 2021 and 2030
Figure 10.34 Modular Facilities Market for Biosimilars, 2021-2030 (USD Million)
Figure 10.35 Modular Facilities Market for Cell and Gene Therapies, 2021-2030 (USD Million)
Figure 10.36 Modular Facilities Market for Monoclonal Antibodies, 2021-2030 (USD Million)
Figure 10.37 Modular Facilities Market for Vaccines, 2021-2030 (USD Million)
Figure 10.38 Modular Facilities Market for Other Products, 2021-2030 (USD Million)
Figure 10.39 Modular Facilities Market: Distribution by Key Geographical Regions, 2021 and 2030
Figure 10.40 Modular Facilities Market in North America, 2021-2030 (USD Million)
Figure 10.41 Modular Facilities Market in Europe, 2021-2030 (USD Million)
Figure 10.42 Modular Facilities Market in Asia, 2021-2030 (USD Million)
Figure 10.43 Modular Facilities Market in Middle East and North Africa, 2021-2030 (USD Million)
Figure 10.44 Modular Facilities Market in Latin America, 2021-2030 (USD Million)
Figure 10.45 Modular Facilities Market in Rest of the World, 2021-2030 (USD Million)
Figure 10.46 Modular Facilities in Pharmaceutical and Biotechnology Market, 2021, 2025 and 2030: Conservative, Base and Optimistic Scenarios (USD Million)
Figure 11.1 Modular Facilities: Technological Advancements
Figure 12.1 Modular Facilities Market: Future Growth Opportunities
Figure 13.1 Concluding Remarks: Current Market Landscape
Figure 13.2 Concluding Remarks: Partnerships and Collaborations
Figure 13.3 Concluding Remarks: Market Sizing and Opportunity Analysis

List Of Tables

Table 3.1 Cleanroom Classification and Current Standards
Table 3.2 Cleanroom Classification: ISO and FED STD 209E:
Table 4.1 Modular Facility Manufacturers: List of Modular Manufacturers
Table 4.2 Modular Facility Manufacturers: Information on Region and GMP Compliance
Table 4.3 Modular Facility Manufacturers: Information on Type of Industry Served
Table 4.4 Modular Facility Manufacturers: List of Quality Certifications Obtained
Table 5.1 Modular Cleanrooms: List of Service Providers
Table 5.2 Modular Cleanroom Providers: Type of Industry Served and Modular Cleanroom Providers
Table 5.3 Modular Cleanroom Providers: List of Modular Cleanrooms and Associated Components Offered
Table 5.4 Modular Cleanroom Providers: Regulatory Approvals and Certifications Obtained
Table 6.1 Cytiva: Key Highlights
Table 6.2 Cytiva: Modular Projects
Table 6.3 Cytiva: Recent Developments and Future Outlook
Table 6.4 G-CON: Key Highlights
Table 6.5 G-CON: Modular Projects
Table 6.6 G-CON: Recent Developments and Future Outlook
Table 6.7 Pharmadule: Key Highlights
Table 6.8 Pharmadule: Modular Projects
Table 6.9 Pharmadule: Recent Developments and Future Outlook
Table 6.10 NNE: Key Highlights
Table 6.11 NNE: Modular Projects
Table 6.12 NNE: Recent Developments and Future Outlook
Table 6.13 IPM Technologies: Key Highlights
Table 6.14 KeyPlants: Key Highlights
Table 6.15 KeyPlants: Other Services
Table 6.16 KeyPlants: Recent Developments and Future Outlook
Table 6.17 Germfree Laboratories: Key Highlights
Table 6.18 Germfree Laboratories: Key Features of Modules
Table 6.19 Germfree Laboratories: Recent Developments and Future Outlook
Table 6.20 ModuleCo Pharma: Key Highlights
Table 7.1 Modular Facility Providers: List of Partnerships and Collaborations, 2012-2021 (Till January)
Table 7.2 Partnerships and Collaborations: Information on Partner Company and Type of Agreement
Table 8.1 Feasibility Study: List of Modular Facilities
Table 8.2 Feasibility Study: List of Clients and Location of Modular Facility
Table 8.3 Feasibility Study: Comparison of Construction Investment and Financial Returns
Table 9.1 Conventional Facilities: List of Projects Undertaken in Pharmaceutical / Biotechnology Industry (Top 20 Companies): Historical Data, 2016-2020 (Till December)
Table 14.1 G-CON Manufacturing: Company Snapshot
Table 14.2 Modwave: Company Snapshot
Table 14.3 Enviromental Systems Corporation: Company Snapshot
Table 14.4 Exyte: Company Snapshot
Table 14.5 Avon Modular: Company Snapshot
Table 14.6 Zeton: Company Snapshot
Table 15.1 Modular Facility Manufacturers: Distribution by Year of Establishment
Table 15.2 Modular Facility Manufacturers: Distribution by Company Size
Table 15.3 Modular Facility Manufacturers: Distribution by Continent of Headquarters
Table 15.4 Modular Facility Manufacturers: Distribution by Country of Headquarters
Table 15.5 Modular Facility Manufacturers: Distribution by Geographical Coverage
Table 15.6 Modular Facility Manufacturers: Distribution by Geographical Coverage and GMP Compliance
Table 15.7 Modular Facility Manufacturers: Distribution by Type of Industry Served
Table 15.8 Modular Facility Manufacturers: Distribution by Geographical Coverage and Type of Industry Served
Table 15.9 Modular Facility Manufacturers: Distribution by Location of Facility, Company Size and Type of Industry Served
Table 15.10 Modular Cleanroom Providers: Distribution by Year of Establishment
Table 15.11 Modular Cleanroom Providers: Distribution by Company Size
Table 15.12 Modular Cleanroom Providers: Distribution by Location of Headquarters
Table 15.13 Modular Cleanroom Providers: Distribution by Type of Industry Served
Table 15.14 Modular Cleanroom Providers: Distribution by Type of Modular Cleanroom Offered
Table 15.15 Modular Cleanroom Providers: Distribution by Type of Industry Served and Type of Modular Cleanrooms Offered
Table 15.16 Modular Cleanroom Providers: Distribution by Type of Cleanroom Component Offered
Table 15.17 Modular Cleanroom Providers: Distribution by Type of Industry Served and Type of Cleanroom Component Offered
Table 15.18 Modular Cleanroom Providers: Distribution by Type of Industry Served and Type of Cleanroom Component Offered
Table 15.19 Modular Cleanroom Providers: Distribution by Location of Headquarters and Type of Industry Served
Table 15.20 Modular Cleanroom Providers: Distribution by Location of Headquarters, Type of Industry Served and Type of Modular Cleanroom
Table 15.21 Partnerships and Collaborations: Cumulative Year-wise Trend, 2012-2021 (Till January)
Table 15.22 Partnerships and Collaborations: Distribution by Type of Partnership
Table 15.23 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 15.24 Partnerships and Collaborations: Distribution by Type of Product
Table 15.25 Partnerships and Collaborations: Distribution by Type of Product and Type of Partnership
Table 15.26 Partnerships and Collaborations: Distribution by Type of Modular Facility
Table 15.27 Partnerships and Collaborations: Distribution by Type of Product and Type of Facility
Table 15.28 Partnerships and Collaborations: Distribution by Number of Partnerships
Table 15.29 Partnerships and Collaborations: Distribution by Location of Headquarters of Partner
Table 15.30 Partnerships and Collaborations: Distribution by Location of Facility
Table 15.31 Partnerships and Collaborations: Distribution by Type of Partnership and Location of Facility
Table 15.32 Partnerships and Collaborations: Distribution by Type of Product and Location of Facility
Table 15.33 Partnerships and Collaborations: Country-wise Distribution
Table 15.34 Partnerships and Collaborations: Continent-wise Distribution
Table 15.35 Partnerships and Collaborations: Distribution by Type of Partnership, Type of Product, Location of Facility and Type of Agreement
Table 15.36 Feasibility Study: Distribution by Type of Facility
Table 15.37 Feasibility Study: Distribution by Area of Facility
Table 15.38 Feasibility Study: Distribution by Area and Type of Facility
Table 15.39 Feasibility Study: Distribution by Modular Facility Providers
Table 15.40 Feasibility Study: Distribution by Geography
Table 15.41 Facility Construction Trends in Pharmaceutical Industry: Distribution by Number of Facilities
Table 15.42 Facility Construction Trends in Pharmaceutical Industry: Distribution by Type of Facility
Table 15.43 Facility Construction Trends in Pharmaceutical Industry: Distribution by Purpose of Facility
Table 15.44 Facility Construction Trends in Pharmaceutical Industry: Distribution by Investment
Table 15.45 Facility Construction Trends in Pharmaceutical Industry: Distribution by Facility Area
Table 15.46 Facility Construction Trends in Pharmaceutical Industry: Distribution by Location of Headquarters
Table 15.47 Modular Facilities in Pharmaceutical and Biotechnology Market, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.48 Modular Facilities Market: Distribution by Type of Modular Construct, 2021-2030 (USD Million)
Table 15.49 Modular Facilities Market for Hybrid Skid Modular Construct, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.50 Modular Facilities Market for Plug-and-Play Modular Construct, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.51 Modular Facilities Market for Skid-Mounted Modular Construct, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.52 Modular Facilities Market for Truckable Modular Construct, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.53 Modular Facilities Market for Others, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.54 Modular Facilities Market: Distribution by Type of Construction Component, 2021 and 2030
Table 15.55 Modular Facilities Market for Base Building, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.56 Modular Facilities Market for Electrical System, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.57 Modular Facilities Market for Mechanical System, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.58 Modular Facilities Market for Process Equipment, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.59 Modular Facilities Market for Process Piping, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.60 Modular Facilities Market for Process Utilities, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.61 Modular Facilities Market for Other Components, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.62 Modular Facilities Market: Distribution by Purpose of Facility, 2021 and 2030
Table 15.63 Modular Facilities Market for Aseptic Filling, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.64 Modular Facilities Market for Manufacturing, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.65 Modular Facilities Market for Research and Development, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.66 Modular Facilities Market for Others, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.67 Modular Facilities Market: Distribution by Facility Area, 2021 and 2030
Table 15.68 Modular Facilities Market for Very Small Plants, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.69 Modular Facilities Market for Small Plants, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.70 Modular Facilities Market for Mid-Sized Plants, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.71 Modular Facilities Market for Large Plants, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.72 Modular Facilities Market for Very Large Plants, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.73 Modular Facilities Market: Distribution by Scale of Operation, 2021 and 2030
Table 15.74 Modular Facilities Market for Clinical Operations, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.75 Modular Facilities Market for Commercial Operations, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.76 Modular Facilities Market: Distribution by Type of Industry, 2021 and 2030
Table 15.77 Modular Facilities Market for Pharmaceutical, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.78 Modular Facilities Market for Biotechnology, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.79 Modular Facilities Market: Distribution by Type of Product, 2021 and 2030
Table 15.80 Modular Facilities Market for Biosimilars, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.81 Modular Facilities Market for Cell and Gene Therapies, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.82 Modular Facilities Market for Monoclonal Antibodies, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.83 Modular Facilities Market for Vaccines, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.84 Modular Facilities Market for Other Products, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.85 Modular Facilities Market: Distribution by Key Geographical Regions, 2021 and 2030
Table 15.86 Modular Facilities Market in North America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.87 Modular Facilities Market in Europe, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.88 Modular Facilities Market in Asia, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.89 Modular Facilities Market in Middle East and North Africa, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.90 Modular Facilities Market in Latin America, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.91 Modular Facilities Market in Rest of the World, 2021-2030, Conservative, Base and Optimistic Scenarios (USD Million)
Table 15.92 Modular facilities in Pharmaceutical and Biotechnology Market, 2021, 2025 and 2030, Conservative, Base and Optimistic Scenarios (USD Million)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 209Technologies 
  2. 3P Biopharmaceuticals
  3. A.D Clean Rooms (Katz Group)
  4. Labyrinth BioPharma (Formerly known as AB Biotechnology)
  5. Abbott
  6. AbbVie
  7. ABN Cleanroom Technology
  8. Abtech
  9. ACH Engineering
  10. Acumen Technology
  11. AES Clean Technology
  12. Air Micron Cleantech
  13. Aircare Projects 
  14. Airgas
  15. Airology
  16. Airplan
  17. Airtech Systems
  18. Aizon
  19. Ajinomoto North America
  20. AKERTEC
  21. Albian Group
  22. Alembic Pharmaceuticals 
  23. Allied Cleanrooms
  24. AM Technical Solutions
  25. AME For Industry 
  26. American Cleanroom Systems
  27. Amgen
  28. Amicron Cleantech
  29. Angstrom Technology 
  30. AqVida
  31. Ardmac
  32. Asgard Cleanroom Solutions
  33. AstraZeneca
  34. AveXis
  35. Avon Modular
  36. AWS Bio-Pharma Technologies
  37. Axenic Systems
  38. Bangalore Air Tech Solution
  39. Bassaire 
  40. Baxter
  41. Bayer
  42. BC Technology
  43. BeiGene
  44. Belcher Equipment
  45. Bigneat
  46. BioCon Solutions
  47. Biogen
  48. Biologics Modular 
  49. Bioscience Institute
  50. Bladeroom
  51. Bode Equipment
  52. Boehringer Ingelheim
  53. Brammer Bio
  54. Bristol Myers Squibb
  55. Butler Manufacturing
  56. Cambridge Cleanroom
  57. CCRM
  58. C-Cube
  59. Cell and Gene Therapy Catapult
  60. CID Associates
  61. Cipharm
  62. Clean Air Flow
  63. Clean Air Products
  64. Clean Air Systems
  65. Clean Air Technology
  66. Clean Modules
  67. Clean Room Depot 
  68. Clean Rooms International
  69. Clean Rooms Plus
  70. Clean Zone Technology 
  71. CleanAir Solutions
  72. Cleanetics
  73. Cleanroom Ceiling Systems (A division of Varni Enterprises)
  74. Cleanroom Equipment
  75. Cleanroom Results
  76. Cleanroom Solutions
  77. Cleanroom Synergy 
  78. Cleanrooms Australia 
  79. Cleanrooms By United
  80. Cleanrooms Containments
  81. Clean Rooms West
  82. CleanZones
  83. ClearSphere
  84. Clestra Cleanroom 
  85. Codiak BioSciences
  86. Commercial Structures Corporation
  87. Connect 2 Cleanrooms
  88. CONSAB International 
  89. CRB
  90. Cubic Pharmaceuticals
  91. Cyberfreight Pharma Logistics
  92. Cytiva
  93. Daldrop
  94. Design Filtration Microzone
  95. DPR Construction
  96. E-Pack Polymers
  97. Ebtech Industrial Modular Building Solutions 
  98. EirGen Pharma
  99. Eli Lilly
  100. Emergent BioSolutions
  101. Enbloc
  102. Envair Electrodyne
  103. Environmental Systems Corporation (ESC)
  104. Erytech Pharma
  105. Exyte (A subsidiary of M+W Group)
  106. Expression Therapeutics
  107. Ferring Pharmaceuticals
  108. Filtration Technology 
  109. Firmament Technology
  110. Firs Bioengineering
  111. Florida Cleanroom Systems
  112. Flowstar Corporation 
  113. Fluor
  114. Fraunhofer Project Centre 
  115. Galderma
  116. G-CON Manufacturing
  117. GenCure
  118. Genentech
  119. Gerbig Engineering Company
  120. Germfree 
  121. Gilead Sciences
  122. GlaxoSmithKline
  123. GMP Technical Solutions
  124. GMPMax Pharma
  125. Green Carrier Consultancy and Tech Solutions
  126. Guardtech Cleanrooms
  127. Halco Products
  128. HAZE comfort
  129. Healthcare Diagnostics 
  130. Hectra Enviro Systems
  131. Hemair Systems
  132. HEMCO Corporation
  133. HEPAire Products Corporation
  134. Hermetel Oy
  135. Hexakore
  136. Hodess Construction
  137. HOK
  138. Holden
  139. Hume Group MC
  140. Huntair
  141. Iberconcept
  142. Innovative Cleanroom Technologies
  143. Ingelyt
  144. Innclose
  145. North Central Instruments (Formerly known as Innotech Products)
  146. Instaspace
  147. Instituto Butantan
  148. Integrated Cleanroom Technologies 
  149. IPM Technologies
  150. IPS
  151. IsoTech Design
  152. Jacobs
  153. JHL Biotech
  154. Johnson & Johnson
  155. Just-Evotec Biologics
  156. KABTech Corporation
  157. KeyPlants
  158. Kingspan
  159. KTEC Cleanroom Systems
  160. L7 Informatics
  161. Labard Instruchem
  162. Labover
  163. LabRum
  164. Labworks International
  165. Lasco Services
  166. Legend Biotech
  167. Lennox Clean Air Technologies
  168. Libbs Farmacêutica
  169. Liberty Industries
  170. LifeAire Systems
  171. LM Air Technology
  172. Longden Company
  173. Lonza
  174. La Salle Blanche
  175. M+W Group
  176. Mach-Aire
  177. MAK Clean Air Systems
  178. Mars Sterile Solutions
  179. Mayo Clinic
  180. McLennan & Company 
  181. M Davis & Sons
  182. MDI
  183. MECART
  184. Medical Air Technology
  185. Medicus Mundi
  186. Medipharma
  187. Merck
  188. Merit Holdings
  189. Modubuild
  190. Modular Cleanrooms 
  191. Modular Panel Systems
  192. ModuleCo Pharma
  193. Modulus Cleanrooms
  194. Monmouth Scientific 
  195. MRC Systems
  196. Merck Sharp & Dohme
  197. MTX Contracts
  198. Nano Clean
  199. National Institutes of Health (NIH)
  200. National Partitions
  201. NGS Cleanroom Solutions
  202. Nicomac
  203. NNE
  204. Norwood Group
  205. Novartis
  206. Novo Nordisk
  207. OCTANORM 
  208. Octapharma
  209. Omrix Biopharmaceuticals
  210. Ori Biotech
  211. Oxford BioMedica
  212. Pacific Environmental Technologies
  213. Pall Biotech
  214. Panel Built 
  215. Parteco
  216. PC Company
  217. Penn Medicine
  218. Pentec Health
  219. Perotech Sciences
  220. Pfizer
  221. Pharmacon
  222. Pharmadule (Acquired by Morimatsu Group)
  223. Plascore
  224. PortaFab
  225. Porta-King Building Systems
  226. Power And Motion
  227. Precise Engineering Design
  228. Precision Air Technology
  229. Precision Cleanrooms
  230. ProCleanroom
  231. Purever Tech
  232. QleanAir Scandinavia
  233. Regeneron
  234. Replenish
  235. Riddhi Metals
  236. Rinac India
  237. Robert Soper
  238. Roche
  239. Rubius Therapeutics
  240. Sanaria
  241. Sanofi
  242. Sapphire Cleanrooms 
  243. Saudi Bio
  244. Schering-Plough
  245. Schilling Engineering
  246. SGS
  247. Shanghai HJ Modular Cleanroom
  248. Shanghai Junshi Biosciences
  249. Shelving + Rack Systems 
  250. Siemens
  251. Simplex Isolation Systems
  252. Skylark Engineering Technologies
  253. SLAC
  254. Span Construction and Engineering
  255. Speed Space
  256. Srprefabs Modular Cleanroom
  257. Starrco 
  258. Stefatos
  259. Steriltech
  260. Stodec Products
  261. Stragen Pharma
  262. Strike Bio
  263. Swedish Modules
  264. Syntec Airflow System
  265. SZ Airkey Environmental Tech & Eng
  266. Takeda
  267. Technical Air Products
  268. Ted Thorsen Material Handling
  269. Telstar Life Science Solutions
  270. Terra Universal 
  271. Zhejiang Teruisi Pharmaceutical 
  272. Teva Pharmaceutical Industries
  273. The Softwall Shop 
  274. Tocci Building
  275. Travis Clean Air (TCS)
  276. Triumph Modular
  277. Tudela International
  278. Ultrapure Technology 
  279. Unikelvin Ventures
  280. United Partition Systems
  281. Univercells
  282. Unibio
  283. University of Tennessee Health Science Center
  284. Vanguard Modular Building Systems
  285. Vanrx Pharmasystems (Acquired by Cytiva)
  286. Veltek Associates
  287. Vernick 
  288. VRP Cleanroom Systems
  289. W.W. Cannon
  290. Weaver Technologies
  291. Westbury Cleanrooms
  292. Western Environmental Corporation
  293. WH Engineering
  294. Whitenair Technologies
  295. WHP Engineering
  296. WuXi Vaccines
  297. XBiotech 
  298. Xytel
  299. YRS Enterprises
  300. Zeton
  301. Ziccum

PRICING DETAILS

USD 5,899

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experienceAccept

Copyright © 2022 Roots Analysis. All Rights Reserved.